ManRos Therapeutics’ strategy is based on three pillars.
-
With extensive in-house experience and expertise in chemistry, biochemistry, cell biology, pharmacology, and an extended network of CROs and renowned collaborators, ManRos Therapeutics will bring some of its proprietary compounds in clinical phase II in several strategic therapeutic domains, such as cancers, leukemia, or Alzheimer’s disease.
-
To further develop the products, ManRos Therapeutics will partner with pharmaceutical companies with commercial capabilities. For programs outside our core competencies, we may enter into partnering arrangements earlier.
-
In addition, ManRos Therapeutics keeps filling its pipeline by generating new low molecular weight pharmacological inhibitors of key disease-relevant kinases. We have privileged access to a 45,000 compound library at the Station Biologique de Roscoff. We are also working with a large network of collaborators with experience in other areas of therapeutics.
